镥-177 PSMA诊疗一体化:实践细节与复杂性
本文综述了177Lu-PSMA-617放射配体治疗在前列腺癌中的诊疗一体化原理与实践细节。基于2014年以来多项回顾性研究及一项II期前瞻性研究显示的安全性和显著疗效,两项随机试验TheraP和VISION正在进行中。文章旨在分享PSMA诊疗一体化实践方面的经验与细微之处。
要点
- 177Lu-PSMA-617是研究最广泛的PSMA靶向小分子放射配体。
- 2014年以来回顾性研究及II期前瞻性研究显示其安全性和显著疗效。
- TheraP和VISION两项随机试验正在进行中,等待关键结果。
核心结论
- 177Lu-PSMA-617放射配体治疗在转移性前列腺癌中显示安全性和显著疗效,但实践细节复杂。
研究设计与样本
- 综述文章,总结PSMA诊疗一体化的实践经验和细微之处。
主要发现
- 2014年以来多项回顾性研究和一项II期前瞻性研究证实了177Lu-PSMA放射配体治疗的安全性和显著疗效。
- 这些证据促使两项随机试验TheraP(NCT03392428)和VISION(NCT03511664)在转移性去势抵抗性前列腺癌中开展。
临床怎么用
- 核医学医师、肿瘤内科医师、放射肿瘤医师和泌尿外科医师需要掌握该新型治疗策略的复杂性和细微之处。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Theranostic principles utilize a molecular biomarker specific for a tumor target, initially for imaging to assess target expression and, if deemed suitable, for targeted therapy. This presents an exciting opportunity for a highly personalized treatment strategy in the era of precision medicine. Prostate-specific membrane antigen (PSMA) theranostics has attracted increasing attention as a promising targeted treatment in metastatic prostate cancer (PC). 177Lu-DOTA-PSMA-617 (177Lu-PSMA-617) is a PSMA-targeted small molecule with favorable properties and is the most extensively investigated PSMA radioligand for radionuclide therapy (RNT) in PC. Since 2014 multiple retrospective studies and more recently a phase II prospective study demonstrated safety and impressive efficacy of 177Lu-PSMA RNT. The evidence generated by these trials led to two currently underway randomized trials in metastatic castrate-resistant PC: TheraP (NCT03392428) and VISION (NCT03511664). While we wait for these pivotal trials to read out, nuclear medicine physicians, medical oncologists, radiation oncologists, and urologists are facing a steep learning curve to master the intricacies and nuances of this novel therapeutic strategy. This review article aims to share and discuss the evolving experience in practical aspects of PSMA theranostics.
引用
- Iravani A, Violet J, Azad A, et al. Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies. Prostate Cancer Prostatic Dis. 2019. PMID: 31595044. doi:10.1038/s41391-019-0174-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。